cfDNA (circulating DNA or cell-free DNA) are fragments of DNA that are released into the blood.
Elevated levels are seen in cancer and they can be detected using 'liquid biopsies' to aid diagnosis. Fetal cfDNA can be detected in maternal blood through non-invasive prenatal testing.
A Texas court has awarded $100 million more damages to a company whose patents for non-invasive prenatal testing technology were infringed by a competitor...
Prenatal genetic test results need to be communicated better, according to the US Food and Drug Administration...
Health regulators in five countries are investigating non-invasive prenatal test NIFTY, over data protection concerns....
Non-invasive prenatal testing to detect chromosomal abnormalities in twin pregnancies is not as accurate as in singleton pregnancies...
A long-running court case over non-invasive prenatal testing patents has been settled...
Canadian researchers have published two new studies using machine learning to improve detection and treatment of cancer...
The largest genetic analysis of China's population to date has been carried out on over 140,000 pregnant women, revealing new insights into migration patterns and disease risk in Chinese people...
DNA shed from early embryos could one day provide an alternative way of genetically testing them without having to do a biopsy, suggests a small pilot study...
A new blood test which can detect ten cancers at an early stage is offering hope as a way to screen for multiple cancers...
The UK Patents Court has ruled that two separate non-invasive prenatal tests infringe patents licensed by the US firm Illumina...
Subscribe for free to what PET does best – informing you of the latest in fertility, genomics and embryo research.
